BioVersys AG (SWX:BIOV)

Market Cap	157.31M -22.2%
Revenue (ttm)	3.18M +161.7%
Net Income	-21.83M
EPS	-3.89
Shares Out	5.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	459
Open	26.90
Previous Close	27.10
Day's Range	26.40 - 26.90
52-Week Range	21.20 - 36.00
Beta	n/a
Analysts	Strong Buy
Price Target	58.26 (+116.58%)
Earnings Date	Sep 3, 2026

About BioVersys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ans...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 33
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BIOV

Financial Performance

In 2025, BioVersys AG's revenue was 3.18 million, an increase of 161.75% compared to the previous year's 1.21 million. Losses were -21.83 million, 16.6% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for BIOV stock is "Strong Buy." The 12-month stock price target is CHF 58.26, which is an increase of 116.58% from the latest price.

Price Target

CHF 58.26

(116.58% upside)

Analyst Consensus: Strong Buy